WaveMan
WaveMan · Company
TLSI · Trisalus Life Sciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TLSI TriSalus Life Sciences (TLSI) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001826667
Quote by TradingView
Cluster · 5 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
58
13F, latest reported quarter

What the filings say about TLSI

Insiders, 180 days
+$1.8M net bought
5 buyers · 3 sellers · 0% of sales under a 10b5-1 plan

TriSalus Life Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, TriSalus Life Sciences, Inc. insiders bought a net $1.8M of stock across 53 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Cox Bryan F.
Chief of Research
SELL
2026-10-07 SECtraded 2026-10-05
296
$1.3K
-12.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 16, 2026.
  • The trade is 0.2% of the 162,805 shares held after it.
  • 2 other insiders sold within 30 days.
  • 58 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief of Research Cox Bryan F. sold about $1.3K of TLSI on Oct 5, 2026; 2 other insiders sold within 30 days and 58 funds added in the latest 13F quarter.
Marshak Richard
Chief Commercial Officer
SELL
2026-10-07 SECtraded 2026-10-05
325
$1.4K
-12.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on May 15, 2026.
  • The trade is 0.3% of the 127,994 shares held after it.
  • 2 other insiders sold within 30 days.
  • 58 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Marshak Richard sold about $1.4K of TLSI on Oct 5, 2026; 2 other insiders sold within 30 days and 58 funds added in the latest 13F quarter.
Stevens Jennifer
Chief Regulatory Officer
SELL
2026-10-07 SECtraded 2026-10-05
316
$1.4K
-12.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 16, 2026.
  • The trade is 0.3% of the 123,794 shares held after it.
  • 2 other insiders sold within 30 days.
  • 58 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Regulatory Officer Stevens Jennifer sold about $1.4K of TLSI on Oct 5, 2026; 2 other insiders sold within 30 days and 58 funds added in the latest 13F quarter.
Marshak Richard
Chief Commercial Officer
SELL
2026-05-19 SECtraded 2026-05-15
543
$1.4K
+11.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 16, 2026.
  • The trade is 0.4% of the 125,101 shares held after it.
  • No other insider sold within 30 days.
  • 58 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Marshak Richard sold about $1.4K of TLSI on May 15, 2026; 58 funds added in the latest 13F quarter.
Wahlstrom Mats
Director
BUY
2026-05-18 SECtraded 2026-05-15
60,000
$151.8K
+14.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 22, 2024.
  • +29.1% median (+31.7% mean) 90-day return after 3 previous buys.
  • The trade is 40.7% of the 147,555 shares held after it.
  • 4 other insiders bought within 30 days.
  • 58 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wahlstrom Mats bought about $151.8K of TLSI on May 15, 2026; 4 other insiders bought within 30 days and 58 funds added in the latest 13F quarter.
53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 48 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.8M over 180 days
-$4.1K over 90 days
more than 94% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
58 funds bought in last quarter
below 54% of Medical Devices
Revenue
+53.4% year over year
more than 87% of Medical Devices
Margin
-86.9% net margin
below 78% of Medical Devices
Buybacks
no share repurchases reported
Short interest
6.7% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 65% of Medical Devices
The situation: each line is one rule over one dataset
5 insiders independently bought a net $1.8M while the stock fell 20% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 7Chief Commercial Officer Marshak Richard sold $1.4K (Oct 5)
Oct 7Chief Regulatory Officer Stevens Jennifer sold $1.4K (Oct 5)
Oct 7Chief of Research Cox Bryan F. sold $1.3K (Oct 5)

Watch TLSI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-29.4%12M
-51%-19%+14%+46%2025-102025-122026-022026-042026-062026-082026-10 2026-05-15 · Stansky Michael P bought $1.0M2026-02-23 · Stansky Michael P bought $1,000.0K2026-05-15 · Stansky Michael P bought $500.0K2026-02-23 · Stansky Michael P bought $480.5K2026-05-15 · Wahlstrom Mats bought $151.8K2026-02-23 · Valle William bought $125.0K2026-02-23 · Szela Mary T bought $125.0K2026-05-15 · Szela Mary T bought $102.8K2026-03-17 · Szela Mary T sold $61.4K2026-02-23 · Gordon Gary B. bought $40.0K2026-05-15 · Gordon Gary B. bought $24.6K2026-03-11 · Szela Mary T sold $18.0K2026-05-15 · Patience David bought $17.3K2026-02-23 · Patience David bought $15.0K2026-03-12 · Devlin Jodi sold $7.2K2026-03-12 · Marshak Richard sold $6.5K2026-03-12 · Stevens Jennifer sold $6.3K2026-03-12 · Cox Bryan F. sold $6.0K2026-03-11 · Marshak Richard sold $6.0K2026-03-11 · Stevens Jennifer sold $5.0K2026-03-11 · Devlin Jodi sold $4.8K2026-03-11 · Cox Bryan F. sold $4.7K2026-03-16 · Stevens Jennifer sold $3.2K2026-03-16 · Cox Bryan F. sold $2.4K2026-03-16 · Marshak Richard sold $1.7K2026-05-15 · Marshak Richard sold $1.4K2026-10-05 · Marshak Richard sold $1.4K2026-10-05 · Stevens Jennifer sold $1.4K2026-10-05 · Cox Bryan F. sold $1.3K2026-03-16 · Devlin Jodi sold $1.1K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TLSI: institutional holders (13F)

13F holdings, latest reported quarter
First Light Asset Management, LLC
6,552,491 sh
$29.8M
BlackRock, Inc.
2,659,218 sh
$12.1M
Nantahala Capital Management, LLC
2,000,000 sh
$9.1M
Cerity Partners LLC
2,431,128 sh
$8.0M
VANGUARD CAPITAL MANAGEMENT LLC
1,729,385 sh
$7.9M

Congress trades in TLSI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TLSI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TLSI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Smaller-Companies Growth Fund
$910.0K position · as of 2026-06-30
0.4%
Ultra-Small Company Market Fund
$295.8K position · as of 2026-06-30
0.2%
NORTH SQUARE KENNEDY MICROCAP FUND
$47.2K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$728.9K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$49.0K position · as of 2026-06-30
0.0%
GuideMark Small/Mid Cap Core Fund
$21.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mary Szela
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.8M
$6.9M
$2.5M
-17%
n/a
2024
$4.1M
$1.5M
$1.8M
-41%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $1.8M bought by insiders over 180 days, 58 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

TLSI financials

Revenue growth
+53.4%
XBRL, annual
Net margin
-86.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$45.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-62.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$23.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
5.05x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.69x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-54.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-73.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$209.7M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-10.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$45.2M$29.4M$18.5M$12.4M
Gross profit$38.2M$25.3M$15.9M$10.1M
Operating income-$26.9M-$36.2M-$54.5M-$36.4M
Net income-$39.2M-$30.0M-$59.4M-$47.2M
EPS (diluted)-1.84-1.31-6.77-161.55
Operating cash flow-$18.0M-$40.8M-$50.6M-$32.3M
Cash$20.4M$8.5M$11.8M$9.4M
Long-term debt$33.0M$22.1M$0n/a
Buybacksn/an/an/a$232.4M
SEC XBRL, fiscal years, as known on 2026-10-28

TLSI Stock Sonar score 6/7 axes

Find similar shapesCompare

TLSI ranks highest on insider conviction (94th percentile) and growth (87th), and lowest on financial health (20th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
27
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-54.4% · 28 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-73.3% · 25 pct, sector of 188
Financial health
20
Inputs
  • Debt to equity5.05x · 4 pct, sector of 159
  • Cash flow to debt-0.69x · 36 pct, sector of 150
Growth
87
Inputs
  • Revenue growth, YoY+53.4% · 87 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
94
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.8M · 94 pct, sector of 140
  • Insider buyers, 180d5 · 94 pct, sector of 142
Institutional and government
56
Inputs
  • Funds adding, latest quarter58 · 46 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$450K · 65 pct, sector of 50
Risk and compliance
62
Inputs
  • Short interest, % of float+6.7% · 37 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.9% · 87 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TLSI filings, in plain words

Are TriSalus Life Sciences insiders buying or selling TLSI?

In the 180 days to 2026-10-28, TriSalus Life Sciences insiders were net buyers, a net $1.8M: $1.8M of purchases and $5.6K of sales reported on Form 4, by 5 buyers and 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, TriSalus Life Sciences insiders were net buyers of TLSI, a net $1.8M across purchases and sales reported on Form 4 by 5 buyers and 3 sellers. Purchases outweighed sales more than tenfold by value. 5 insiders reported purchases in that window. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies